White Paper: Nitrosamines — An Industry Position Paper Based on Risk
The generics industry is committed to taking proactive steps to ensure the quality of generic medicines meets the highest safety standards determined by the FDA. The generics industry is eager to work with FDA to adopt a balanced risk-based approach to addressing the nitrosamine issue. We request the FDA revisit and potentially reassess the set safety […]
While We Await the Vaccine, We Can Trust in Generic Drugs
This article first appeared in Managed Healthcare Executive on February 1, 2021. Generic drugs account for 90% of the prescriptions filled in the United States. They are the backbone of health care providers’ treatment protocol and they are remarkably cost effective: Despite being 90% of the prescriptions filled, generics account for only 20% of drug […]
AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response
WASHINGTON, DC (January 21, 2020) — The Association for Accessible Medicines (AAM) strongly endorses the Biden administration’s executive orders to strengthen America’s response to the COVID pandemic. Generic medicines have been instrumental in treating COVID patients with severe conditions, serving as a bridge until the COVID vaccines are widely available. AAM’s members are ready to partner with […]
Commitment to Quality Excellence
Improving patient access to affordable high-quality medicines is a core value of companies that develop and manufacture generic and biosimilar medicines. Our companies produce and distribute the treatments that make up 90% of prescriptions filled in the U.S., at just 13% of the total prescription drug costs. On behalf of our member companies, we serve as a […]
AAM Statement on Senate Finance Hearing on FDA’s Foreign Manufacturing Inspection Process
WASHINGTON, DC (June 2, 2020) — The COVID-19 crisis exposed many shortcomings in our health care system’s ability to respond to a pandemic. At the same time, many parts of that same system — including the supply chain for the vast majority of generic medicines — demonstrated extraordinary resiliency in the face of unprecedented stresses. […]
Take your safe, effective, affordable FDA-approved medicines with confidence.
AAM Statement on the Importance of Generic and Biosimilar Quality and Robust Competition
WASHINGTON, DC (May 17, 2019) — Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and biosimilar medicines. AAM believes in compliance with all drug quality, competition and antitrust laws. We take all instances of illegal behavior seriously. Anyone convicted of violating these laws should be punished appropriately. AAM […]
Generic Prescriptions Save Lives… and Money, Too
In 2014, Ariel Leaty received a frightening diagnosis—acute lymphocytic leukemia. “I went through three years of chemotherapy,” Leaty, 29, of Bloomfield NJ, recalls, “followed by outpatient maintenance.” The ordeal was grueling, but it would have been far worse, if not deadly, without generic drugs. “If I didn’t have generic prescriptions,” Leaty says, “I probably wouldn’t […]
IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly
Kobe, Japan (June 7, 2018) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to elect the IGBA as a Management Committee Member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). After joining the ICH as a full member […]
AAM Launches Code of Business Ethics
Emphasizes the Value to Patients of Affordable Medicines and Competition WASHINGTON, DC (April 9, 2018) — The Association for Accessible Medicines (AAM) announced that it has established a code of business ethics to memorialize ethical and business standards for its members who are manufacturers of generic and biosimilar medicines. Unanimously endorsed by the AAM Board […]
AAM Member Fresenius Kabi Testifies Before Congress on Drug Compounding
On January 30, Fresenius Kabi USA Vice President of Regulatory Affairs Molly Ventrelli testified before Congress on compounding. The House Energy & Commerce Committee held a hearing on “Examining Implementation of the Compounding Quality Act.” Fresenius Kabi is a global health care company specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. […]
